Prm142 - Quantitative Benefit-Risk Modelling of Biosimilars: A Case Study of Infliximab in Crohn’s Disease.

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2262
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy